PsiOxus Therapeutics, Ltd. (Psioxus)

Oncology Corporate Profile

HQ Location

154B Brook Drive Milton Park
Abingdon Oxfordshire, United Kingdom OX14 4SD

Company Description

PsiOxus Therapeutics is an Oxford, UK -based development stage biotechnology company using non-traditional approaches to develop novel therapeutics that address cancer and other clinically unmet diseases. In addition to MT-102 PsiOxus is also developing ColoAd1 - an oncolytic vaccine for the systemic treatment of metastatic cancer - which has demonstrated exceptional anti-cancer properties in late pre-clinical development and is now in phase I/II clinical development. The Company is also researching treatments based upon _†_armed_†? versions of ColoAd1 as well as the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines

Website: http://www.psioxus.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
MT-102anabolic catabolic transforming agent Cancer cachexiaII
ColoAd1chimeric oncolytic vaccineOvarian cancerPreclinical
NG-350atumor-specific immuno-gene therapyVarious cancer typesPreclinical
NG-348tumor-specific immuno-gene therapyVarious cancer typesPreclinical
NG-347tumor-specific immuno-gene therapyVarious cancer typesPreclinical

View additional information on product candidates here »

Pipeline image

Source


http://www.psioxus.com

Recent News Headlines

There are no news items to display